Reference ID: 3101735
Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. 1.2 Non-Small Cell Lung Cancer . Docetaxel Injection as a single agent is indicated …
Download Reference ID: 3101735
Information
Domain:
Source:
Link to this page:
Documents from same domain
Effexor (venlafaxine hydrochloride) Tablets …
www.accessdata.fda.govEffexor ® (venlafaxine hydrochloride) Tablets Rx only . Suicidality and Antidepressant Drugs Antidepressants increased the risk compared …
Cytotec® - Food and Drug Administration
www.accessdata.fda.govcytotec® (misoprostol) warnings cytotec (misoprostol) administration to women who are pregnant can cause abortion, premature birth, or birth defects.
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govweakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms . FULL …
Namenda XR (memantine hydrochloride) capsules …
www.accessdata.fda.govThe most commonly observed adverse reactions seen in patients administered NAMENDA XR in the controlled clinical trial, defined as those occurring at a frequency of at least 5% in the
FOR INTRAVENOUS USE ONLY - Food and Drug …
www.accessdata.fda.govNDA 50-706/S-022 Page 3 MERREM® I.V. (meropenem for injection) FOR INTRAVENOUS USE ONLY To reduce the development of drug-resistant bacteria and maintain the effectiveness of
NOT FOR USE IN NEONATES CONTAINS BENZYL …
www.accessdata.fda.govDepo-Medrol® methylprednisolone acetate injectable suspension, USP NOT FOR USE IN NEONATES CONTAINS BENZYL ALCOHOL . Not For Intravenous Use . DESCRIPTION
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.accessdata.fda.govDacogen is indicated for treatment of patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and …
Venofer - Food and Drug Administration
www.accessdata.fda.govNDA 21-135/S-017 Page 3 Venofer ® (iron sucrose injection, USP) Rx Only DESCRIPTION Venofer® (iron sucrose injection, USP) is a brown, sterile, aqueous, complex of …
Diphenhydramine Hydrochloride Injection
www.accessdata.fda.govHOW SUPPLIED Diphenhydramine Hydrochloride Injection, USP is a clear and colorless solution available as: 50 mg/mL in a 1 mL prefilled single-use syringe.
EN-2890 Vancomycin Hydrochloride for Injection, …
www.accessdata.fda.govbacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.
Related documents
BC Cancer Extravasation Hazard Table
www.bccancer.bc.caBC Cancer Extravasation Hazard Table (Systemic Therapy Policy III-20) Developed: 1 November 2014 Revised: 1 December 2021 BC Cancer Extravasation Hazard Table
James Patient Education Handouts A-Z
healthsystem.osumc.eduDocetaxel Doxorubicin Liposomal (Doxil) James Patient Education Handouts (A – Z) Click on the title to see the handout To narrow your search use “Ctrl + F” and enter a keyword . The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
POTENTIAL IRRITANT MEDICATIONS
mi-hms.orgPOTENTIAL IRRITANT MEDICATIONS * (Consider administration via central venous catheter – should not administer via Midline) *An irritant is an agent capable of producing discomfort or pain along the internal lumen of the vein (s 105 INS SOP …
PRINCIPLES OF CHEMOTHERAPY IN CANCER
oncologypro.esmo.orgDoxorubicin Doxorubicin Liposomal Epirubicin Idarubicin Mitomycin Mitoxantrone. MITOTIC SPINDLE AGENTS Docetaxel Paclitaxel Paclitaxel Albumin Cabazitaxel Vincristine Vinblastine Vinorelbine Mechanism of action: Bind to microtubular proteins, thus inhibit microtubule assembly resulting in dissolution of the
Extravasation/Infiltration Management Chart
pedsrx.johnshopkins.eduDocetaxel X € Moderate to severe pain DOPamine* X € Skin tight, leaking DOXorubicin X X € Skin discolored, bruised, swollen Doxycycline* X X € Deep pitting tissue edema Epinephrine* X € Gross edema >6" in any direction Erythromycin X € Circulatory impairment Esmolol X X € Blood product, irritant, or vesicant infiltration Etomidate ...
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.eupatients receiving Herceptin therapy alone or in combination with paclitaxel or docetaxel, particularly following anthracycline (doxorubicin or epirubicin) containing chemotherapy. These may be moderate to severe and have been associated with death (see section 4.8). In addition, caution should be